Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis-Reference-Cited by-同舟云学术

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

Published:2018-01-17 Issue:3 Volume:100 Page:257-263
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Masarova Lucia¹^ORCID,Alhuraiji Ahmad²^ORCID,Bose Prithviraj¹,Daver Naval¹,Pemmaraju Naveen¹,Cortes Jorge¹,Pierce Sherry¹,Kantarjian Hagop¹,Verstovsek Srdan¹

Affiliation:

1. Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston TX USA

2. Kuwait Cancer Control Center; Shuwaikh Kuwait

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13005/fullpdf

Reference26 articles.

1. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995;Mesa;Am J Hematol,1999

2. Guideline for the diagnosis and management of myelofibrosis;Reilly;Br J Haematol,2012

3. Myelofibrosis: a review of clinical and pathologic features and treatment;Smith;Crit Rev Oncol Hematol,1990

4. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.;Lataillade;Blood,2008

5. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia;Pikman;PLoS Med,2006

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24

2. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials;HemaSphere;2023-10-27

3. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis;Blood Advances;2023-09-29

4. Top advances of the year: Myeloproliferative neoplasms;Cancer;2023-09-28

5. High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis;Journal of Applied Genetics;2023-07-29